数据
资源
版本对比
免费注册
预约演示
免费注册
Neurocrine Biosciences
® Presents
INGREZZA
® (
valbenazine
) Capsules Interim Data Demonstrating Sustained Improvements in
Chorea
Associated With
Huntington's Disease
Through Week 50 at Huntington Study Group 2023
2023-11-02
·
BioSpace
临床结果
临床3期
上市批准
临床2期
SAN DIEGO, Nov. 2, 2023 /PRNewswire/ --
Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study about
INGREZZA
® (
valbenazine
) capsules when used for the long-term treatment of adults with
chorea
associated with
Huntington's disease (HD)
. Interim data suggest one-capsule, once-daily
INGREZZA
improved chorea at the first evaluation at Week 2 with sustained efficacy through Week 50. These data will be presented at the 30th Annual Meeting of the
Huntington Study Group
on November 2–4 in Phoenix. "These interim data provide insight on the clinically meaningful and sustained improvements participants are experiencing with
INGREZZA
for the treatment of
chorea
," said Eiry W. Roberts, M.D., Chief Medical Officer at
Neurocrine Biosciences
®. "We look forward to analyzing additional data as they become available." KINECT-HD2 includes adults with genetically confirmed motor-manifest HD (n=127), most of whom (n=98) completed KINECT-HD, a Phase 3, randomized, double-blind, placebo-controlled study. Both studies were conducted in collaboration with the
Huntington Study Group
(
HSG
) and contributed to the recent
U.S. Food and Drug Administration
approval of
INGREZZA
for
chorea
associated with HD. Concomitant antipsychotic use is also being explored in the open-label study. The current interim results from KINECT-HD2 (Sustained Improvements With Once-Daily
Valbenazine
in
Chorea
Associated With
Huntington's Disease
: Interim Results From a Long-Term Open-Label Study, Poster # 64) suggest that
INGREZZA
improved
chorea
at the first evaluation (Week 2) when participants were taking the lowest dose of 40 mg, with efficacy sustained through Week 50 at ≤ 80 mg (Figure 1). More than half of participants (60.9 percent) and investigators (58.9 percent) rated symptoms as "much improved" or "very much improved" at Week 6, and about three-quarters of participants (74.2 percent) and investigators (76.9 percent) rated symptoms as "much improved" or "very much improved" by Week 50. The most common treatment-emergent adverse events at the time of the analysis were consistent with those observed in KINECT-HD, including falls (30.4 percent),
fatigue
(24.0 percent) and
somnolence
(24.0 percent).
Neurocrine Biosciences
will also present new data from KINECT-HD (A Wearable Movement Sensor Substudy of KINECT-HD, a Phase 3 Trial of
Valbenazine
for the Treatment of
Chorea
Associated With
Huntington's Disease
, Poster #65), which was the first Phase 3 clinical trial to include a wearable movement sensor substudy. Significant improvements in
truncal chorea
and gait asymmetry measures were seen from baseline to maintenance following the Week 10 visit in the
INGREZZA
-treated group (P < 0.05) compared to placebo. These findings support how digital measurements can be used to detect meaningful symptom changes in individuals with HD to improve clinical research and care. Additional HD chorea presentations at the 30th Annual Meeting of the
HSG
include: The
Huntington's Disease
Health Index (HD-HI): Measuring Changes in Disease Burden in Response to
Valbenazine
During the KINECT®-HD Trial (Poster #66) A Minimal Clinically Important Difference for UHDRS® Total Maximal Chorea Score as a Measure of
Chorea
Severity in
Huntington's Disease
(Poster #63) Indirect Treatment Comparison of
Valbenazine
With
Deutetrabenazine
for Improvement in Total Maximal Chorea Score in
Huntington's Disease
(Poster #62) The full abstracts can be accessed on the Journal of
Huntington's Disease
website. About
Chorea
Associated with
Huntington's Disease (HD)
Huntington's disease (HD)
is a
hereditary progressive neurodegenerative disorder
in which the loss of certain neurons within the brain causes motor, cognitive and psychiatric symptoms. Symptoms generally appear between the ages of 30 and 50 years and worsen over a 10- to 25-year period. Most people with HD experience
chorea
, an
abnormal involuntary movement disorder
, characterized by irregular and unpredictable movements.
Chorea
can affect various body parts and interfere with motor coordination, gait, swallowing and speech. HD is estimated to affect approximately 41,000 adults in the U.S., with more than 200,000 at risk of inheriting the disease. About KINECT®-HD KINECT®-HD was a Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of
valbenazine
as a once-daily treatment to reduce
chorea
associated with
Huntington's disease (HD)
and evaluate the safety and tolerability of
valbenazine
in patients with HD. The study enrolled 128 adults 18 to 75 years of age who were diagnosed with motor-manifest HD and who had sufficient
chorea
symptoms to meet study protocol criteria. KINECT-HD used the Unified
Huntington's Disease
Rating Scale (UHDRS®) Total Maximal Chorea (TMC) score as the primary efficacy endpoint. The secondary endpoints included Clinical Global Impression of Change (CGI-C) response status and Patient Global Impression of Change (PGI-C) response status for
valbenazine
treatment. Treatment with
valbenazine
resulted in a placebo-adjusted mean reduction in the TMC score of 3.2 units (P < 0.0001), indicating a substantial improvement in
chorea
. Secondary endpoints of CGI-C response status and PGI-C response status were also statistically significant and supported the improvements in TMC score that were seen over the 12-week study period. Treatment-emergent adverse events in this study were generally consistent with the known safety pro
valbenazine
. The most common adverse reactions in patients with HD included
somnolence
and
sedation
,
urticaria
,
rash
and
insomnia
. View the complete study results from the Phase 3 KINECT-HD study published in The Lancet Neurology online edition. For more information on the KINECT-HD study, please visit HuntingtonStudyGroup.org. About KINECT®-HD2 KINECT®-HD2 is an ongoing open-label study to evaluate the long-term safety and tolerability, as well as the maintenance of effects, of
INGREZZA
in patients with
chorea
associated with
Huntington's disease (HD)
. The 156-week study has enrolled more than 150 adults 18 to 75 years of age who have been diagnosed with motor-manifest HD and who have sufficient
chorea
symptoms to meet study protocol criteria. Concomitant antipsychotic use is allowed in the study. For more information on the KINECT-HD2 study, please visit HuntingtonStudyGroup.org or ClinicalTrials.gov. About
Huntington Study Group
/ HSG Clinical Research, Inc. The
Huntington Study Group
(
HSG
), a not-for-profit organization founded in 1993 in Rochester, NY, and its wholly owned subsidiary, HSG Clinical Research, Inc., designs and conducts clinical trials through the world's first and largest collaborative network with thousands of members at more than 130
HSG
credentialed research sites worldwide.
HSG
collaborated with the respective study sponsors to complete the three pivotal clinical trials that led to the only FDA-approved medications for
Huntington's disease
associated
chorea
. The organization is dedicated to improving the lives of people impacted by
Huntington's disease
through research, education, and collaboration. For more information, visit . About
INGREZZA
® (
valbenazine
) Capsules
INGREZZA
is the only one-capsule, once-daily selective
vesicular monoamine transporter 2 (VMAT2)
inhibitor approved by the
U.S. Food and Drug Administration
for the treatment of adults with
tardive dyskinesia
and the treatment of
chorea
associated with
Huntington's disease (HD)
.
INGREZZA
, developed by
Neurocrine Biosciences
, selectively inhibits
VMAT2
with no appreciable binding affinity for
VMAT1
, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. While the specific way
INGREZZA
works to treat TD and
HD chorea
is not fully understood,
INGREZZA
selectively targets
VMAT2
to inhibit the release of dopamine, a chemical in the brain that helps control movement.
INGREZZA
is believed to reduce extra dopamine signaling, which may lead to fewer uncontrollable movements. Additionally,
INGREZZA
can be taken as one-capsule once-daily, together with most psychiatric medications such as antipsychotics or antidepressants.
INGREZZA
dosages approved for use are 40 mg, 60 mg and 80 mg capsules.
INGREZZA
is not approved in any other dosage form. Important Information Approved Uses
INGREZZA
® (
valbenazine
) capsules is a prescription medicine used to treat adults with: movements in the face, tongue, or other body parts that cannot be controlled (
tardive dyskinesia
). involuntary movements (chorea) of
Huntington's disease
.
INGREZZA
does not cure the cause of involuntary movements, and it does not treat other symptoms of
Huntington's disease
, such as problems with thinking or emotions. It is not known if
INGREZZA
is safe and effective in children. IMPORTANT SAFETY INFORMATION
VMAT2
inhibitors, including
INGREZZA
, can cause serious side effects in people with
Huntington's disease
, including:
depression
, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking
INGREZZA
if you have
Huntington's disease
and are depressed (have untreated
depression
or
depression
that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when
INGREZZA
is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself. Do not take
INGREZZA
if you: are allergic to
valbenazine
, or any of the ingredients in
INGREZZA
.
INGREZZA
may cause serious side effects, including: Sudden swelling from an
allergic reaction
(
angioedema
). Sudden swelling has happened after the first dose or after many doses of
INGREZZA
. Signs and symptoms of
angioedema
include:
swelling
of your face, lips, throat, and other areas of your skin, difficulty swallowing or breathing, and raised, red areas on your skin (hives).
Swelling
in the throat can be life-threatening and can lead to death. Go to the nearest emergency room right away if you develop these signs and symptoms. Your healthcare provider should stop your treatment with
INGREZZA
. Heart rhythm problems (QT prolongation).
INGREZZA
may cause a heart problem known as
QT prolongation
. Symptoms of
QT prolongation
may include: fast, slow, or
irregular heartbeat
,
dizziness
or
fainting
, or
shortness of breath
. Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you faint.
Neuroleptic Malignant Syndrome (NMS)
:
NMS
is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms and they do not have another obvious cause:
high fever
, stiff muscles, problems thinking, very fast or uneven heartbeat, or increased sweating. Abnormal movements (Parkinson-like). Symptoms include: shaking,
body stiffness
, trouble moving or walking, or keeping your balance. Before taking
INGREZZA
, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Sleepiness
(
sedation
) is a common side effect with
INGREZZA
. While taking
INGREZZA
, do not drive a car or operate dangerous machinery until you know how
INGREZZA
affects you. Drinking alcohol and taking other drugs that may also cause
sleepiness
while you are taking
INGREZZA
may increase any
sleepiness
caused by
INGREZZA
. The most common side effect of
INGREZZA
in people with
tardive dyskinesia
is
sleepiness
(
somnolence
). The most common side effects of
INGREZZA
in people with
Huntington's disease
are
sleepiness
(
somnolence
),
allergic itching
,
rash
, and trouble getting to sleep or staying asleep. These are not all of the possible side effects of
INGREZZA
. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088. Please see
INGREZZA
full Prescribing Information, including Boxed Warning. About
Neurocrine Biosciences
Neurocrine Biosciences
is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders
. The company's diverse portfolio includes FDA-approved treatments for
tardive dyskinesia
,
chorea
associated with
Huntington's disease
,
Parkinson's disease
,
endometriosis
* and
uterine fibroids
*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit
Neurocrine.com
, and follow the company on LinkedIn, X (formerly Twitter) and Facebook. (*in collaboration with
AbbVie
) NEUROCRINE,
NEUROCRINE BIOSCIENCES
, the Neurocrine logo,
INGREZZA
, the
INGREZZA
logo and KINECT are registered trademarks of
Neurocrine Biosciences, Inc.
Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from
INGREZZA
for the treatment of
chorea
associated with
Huntington's disease (HD)
, and the value
INGREZZA
for the treatment of
chorea
associated with HD brings to patients. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements include: risks and uncertainties associated with
Neurocrine Biosciences
' business and finances in general, as well as risks and uncertainties associated with the commercialization of
INGREZZA
for the treatment of
chorea
associated with HD; whether
INGREZZA
for the treatment of
chorea
associated with HD receives adequate reimbursement from third-party payors; the degree and pace of market uptake of
INGREZZA
for the treatment of chorea associated with HD; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA for the treatment of chorea associated with HD; risks associated with the Company's dependence on third parties for development and manufacturing activities related to INGREZZA for the treatment of chorea associated with HD, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for INGREZZA for the treatment of chorea associated with HD or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding INGREZZA for the treatment of chorea associated with HD; risks that post-approval INGREZZA for the treatment of chorea associated with HD commitments or requirements may be delayed; risks that INGREZZA for the treatment of chorea associated with HD may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA for the treatment of chorea associated with HD; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2023.
Neurocrine Biosciences
disclaims any obligation to update the statements contained in this press release after the date hereof. ©2023
Neurocrine Biosciences, Inc.
All Rights Reserved. View original content to download multimedia: SOURCE
Neurocrine Biosciences, Inc.
Company Codes: NASDAQ-NMS:NBIX
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Neurocrine Biosciences, Inc.
Huntington Study Group
University of St. Gallen
[+2]
适应症
舞蹈症
亨廷顿舞蹈病
疲劳
[+25]
靶点
VMAT2
VMAT1
药物
缬苯那嗪
氘丁苯那嗪
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
第一三共ADC药物DS-8201专利调研实务指南
智慧芽生物医药
2024年3月全球首批及特殊审评药物报告
智慧芽生物医药
THR-β 激动剂药物进展及专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务